Changing Adjuvant Breast-Cancer Therapy with a Signal for Prevention

Five randomized, full-scale studies have reported that 10 years of adjuvant endocrine therapy is beneficial for postmenopausal women with hormone-receptor–positive breast cancer. However, no prior study has involved more than 5 years of aromatase-inhibitor use or assessed a duration of adjuvant…

from #MedicinebyAlexandrosSfakianakis via xlomafota13 on Inoreader http://ift.tt/1UrZS5b
via IFTTT